Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

about

Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia.

Item

http://www.wikidata.org/entity/Q42336339

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Hyper-CVAD + epratuzumab as a ...... ll acute lymphocytic leukemia.

@en

Hyper-CVAD + epratuzumab as a ...... ll acute lymphocytic leukemia.

@nl

type

Item

label

Hyper-CVAD + epratuzumab as a ...... ll acute lymphocytic leukemia.

@en

Hyper-CVAD + epratuzumab as a ...... ll acute lymphocytic leukemia.

@nl

prefLabel

Hyper-CVAD + epratuzumab as a ...... ll acute lymphocytic leukemia.

@en

Hyper-CVAD + epratuzumab as a ...... ll acute lymphocytic leukemia.

@nl

P1476

Hyper-CVAD + epratuzumab as a ...... ll acute lymphocytic leukemia.

@en

P2093

Alice Garnier

http://www.w3.org/2001/XMLSchema#string

Aude Charbonnier

http://www.w3.org/2001/XMLSchema#string

Claire Le Houerou

http://www.w3.org/2001/XMLSchema#string

David M Goldenberg

http://www.w3.org/2001/XMLSchema#string

Emmanuel Raffoux

http://www.w3.org/2001/XMLSchema#string

Fanny Rialland

http://www.w3.org/2001/XMLSchema#string

Francoise Huguet

http://www.w3.org/2001/XMLSchema#string

Francoise Isnard

http://www.w3.org/2001/XMLSchema#string

Maria-Pilar Gallego-Hernanz

http://www.w3.org/2001/XMLSchema#string

Marie-C Béné

http://www.w3.org/2001/XMLSchema#string

P2860

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia

Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2

Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.

Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties.

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study.

P304

e184-e186

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2016.159905

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

102

http://www.w3.org/2001/XMLSchema#string

P50

Hervé Dombret

P577

2017-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28154086

http://www.w3.org/2001/XMLSchema#string

P932

5477620

http://www.w3.org/2001/XMLSchema#string